Abstract | PURPOSE OF REVIEW: To review some management issues in myasthenic disorders that are not part of the immune interventions. These are mainly related to pharmacotherapy of these conditions and side effects of various medications, but also referred to acute management of respiration in myasthenic crises. RECENT FINDINGS: SUMMARY: Further research of the above findings is still necessary to make them a solid conclusion for the management of the myasthenias.
|
Authors | Zohar Argov |
Journal | Current opinion in neurology
(Curr Opin Neurol)
Vol. 22
Issue 5
Pg. 493-7
(Oct 2009)
ISSN: 1473-6551 [Electronic] England |
PMID | 19593127
(Publication Type: Journal Article, Review)
|
Chemical References |
- Cholinesterase Inhibitors
- Oligodeoxyribonucleotides, Antisense
- Potassium Channel Blockers
- 4-Aminopyridine
- Pyridostigmine Bromide
- Amifampridine
|
Topics |
- 4-Aminopyridine
(analogs & derivatives, therapeutic use)
- Amifampridine
- Cholinesterase Inhibitors
(therapeutic use)
- Electrodiagnosis
- Humans
- Myasthenia Gravis
(chemically induced, therapy)
- Myasthenic Syndromes, Congenital
(therapy)
- Oligodeoxyribonucleotides, Antisense
(therapeutic use)
- Potassium Channel Blockers
(therapeutic use)
- Pyridostigmine Bromide
(therapeutic use)
- Respiratory Insufficiency
(therapy)
|